Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice

Neuropsychopharmacology

Volumn 37, Issue 4, 2012, Pages 929-938

  Matrisciano, Francesco ^a,b   Tueting, Patricia ^a   MacCari, Stefania ^c   Nicoletti, Ferdinando ^b,d   Guidotti, Alessandro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^d IRCCS NEUROMED   (Italy)

Author keywords

epigenetics; metabotropic glutamate receptors; schizophrenia

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA METHYLTRANSFERASE 1; GLUTAMATE DECARBOXYLASE 67; MESSENGER RNA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METHYL CPG BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EARLY LIFE STRESS; ENZYME BINDING; EPIGENETICS; FEMALE; FRONTAL CORTEX; IMMOBILIZATION STRESS; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PREGNANCY; PRENATAL STRESS; PREPULSE INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SOCIAL INTERACTION;

AMINO ACIDS; ANIMALS; ANIMALS, NEWBORN; BICYCLO COMPOUNDS, HETEROCYCLIC; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, METABOTROPIC GLUTAMATE; RESTRAINT, PHYSICAL; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84857057482     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.274     Document Type: Article

References (78)

1. Amitai N, Markou A (2010). Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. Eur J Pharmacol 639: 67-80.
2. Angelucci F, Brené S, Mathé AA (2005). BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10: 345-352.
3. Belichenko PV, Hagberg B, Dahlstrom A (1997). Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol 93: 50-61.
4. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (2007). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72: 477-484.
5. Bishop JR, Ellingrod VL, Moline J, Miller D (2005). Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 77: 253-260.
6. Bishop JR, Wang K, Moline J, Ellingrod VL (2007). Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 17: 358.
7. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 234-258.
8. Bruno V, Battaglia G, Copani A, Giffard RG, Raciti G, Raffaele R et al (1995). Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 7: 1906-1913.
9. Buckley PF, Pillai A, Howell KR (2011). Brain-derived neurotrophic factor: Findings in schizophrenia. Curr Opin Psychiatry 24: 122-127.
10. Caldji C, Tannenbaum B, Sharma S, Francis D, Plotsky PM, Meaney MJ (1998). Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc Natl Acad Sci USA 95: 5335-5340.
11. Carboni G, Tueting P, Tremolizzo L, Sugaya I, Davis J, Costa E et al (2004). Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation. Neuropharmacology 46: 1070-1081.
12. Castagné V, Moser PC, Porsolt RD (2009). Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 57: 381-418.
13. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J et al (2008). MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224-1229.
14. Conn PJ, Tamminga C, Schoepp DD, Lindsley C (2008). Schizophrenia: Moving beyond monoamine antagonists. Mol Interv 8: 99-107.
15. Crook JM, Akil M, Law BC, Hyde TM, Kleinman JE (2002). Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 7: 157-164.
16. Darnaudéry M, Maccari S (2008). Epigenetic programming of the stress response in male and female rats by prenatal restraint stress. Brain Res Rev 57: 571-585.
17. Di Liberto V, Bonomo A, Frinchi M, Belluardo N, Mudó G (2009). Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 165: 863-873.
18. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2008). Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 105: 13614-13619.
19. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR et al (2004). Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 101: 12604-12609.
20. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH et al (2009). Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 9: 311-318.
21. Gerwirtz JC, Marek GJ (2000). Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23: 569-576.
22. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA (2009). Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action? Am J Psychiatry 166: 812-820.
23. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF et al (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93-97.
24. Grayson DR, Chen Y, Dong E, Kundakovic M, Guidotti A (1999). From trans-methylation to cytosine methylation: Evolution of the methylation hypothesis of schizophrenia. Epigenetics 4: 144-149.
25. Guidotti A, Auta J, Chen Y, Davis JM, Dong E, Gavin DP et al (2011). Epigenetic GABAergic targets in schizophrenia and bipolar bisorder. Neuropharmacology 60: 1007-1016.
26. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M et al (2005). GABAergic dysfunction in schizophrenia: New treatment strategies on the horizon. Psychopharmacology 180: 191-205.
27. Guillin O, Demily C, Thibaut F (2007). Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 78: 377-395.
28. Guillin O, Griffon N, Diaz J, Le Foll B, Bezard E, Gross C et al (2004). Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int Rev Neurobiol 59: 425-444.
29. Guo C, Yang Y, Su Y, Si T (2010). Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration. J Biomed Biotechnol 2010: 783297.
30. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH (2005). Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57: 123-131.
31. Hashimoto T, bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JM et al (2005). Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neuosci 25: 372-383.
32. Hashimoto T, Lewis DA (2006). BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 163: 534-537.
33. Iacovelli L, Molinaro G, Battaglia G, Motolese M, Di Menna L, Alfiero M et al (2009). Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: MGlu2 receptors are resistant to homologous desensitization. Mol Pharmacol 75: 991-1003.
34. Jönsson EG, Saetre P, Vares M, Andreou D, Larsson K, Timm S et al (2009). DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: An association study. Neuropsychobiology 59: 142-150.
35. Kishi N, Macklis JD (2005). Dissecting MeCP2 function in the central nervous system. J Child Neurol 20: 753-759.
36. Lemaire V, Koehl M, Le Moal M, Abrous DN (2000). Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc Natl Acad Sci USA 97: 11032-11037.
37. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
38. Liu D, Diorio J, Day JC, Francis DD, Meaney MJ (2000). Maternal care, hippocampal synaptogenesis and cognitive development in rats. Nat Neurosci 3: 799-806.
39. Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A et al (1997). Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-Adrenal responses to stress. Science 277: 1659-1662.
40. Lu B, Martinowich K (2008). Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp 289: 119-129.
41. Ma DK, Jang MH, Guo JU, Kitabatake Y, Chang ML, Pow-Anpongkul N (2009). Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science 323: 1074-1077.
42. Maccari S, Morley-Fletcher S (2007). Effects of prenatal restraint stress on the hypothalamus-pituitary-Adrenal axis and related behavioral and neurobiological alterations. Psychoneuroendocrinology 32: S10-S15.
43. Maccari S, Piazza PV, Kabbaj M, Barbazanges A, Simon H, Le Moal M (1995). Adoption reverses the long-term impairment in glucocorticoid feedback induced by prenatal stress. J Neurosci 15: 110-116.
44. Marek GJ (2010). Metabotropic glutamate (2/3) mGlu(2/3) receptors, schizophrenia and cognition. Eur J Pharmacol 639: 81-90.
45. Matrisciano F, Dong E, Gavin DP, Nicoletti F, Guidotti A (2011). Activation of group-II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol Pharm 80: 174-182.
46. Matrisciano F, Scaccianoce S, Del Bianco P, Panaccione I, Canudas AM, Battaglia G et al (2005). Metabotropic glutamate receptors and neuroadaptation to antidepressants: Imipramine-induced down-regulation of beta-Adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J Neurochem 93: 1345-1352.
47. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A, Scaccianoce S et al (2002). Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42: 1008-1015.
48. McCormick CM, Smythe JW, Sharma S, Meaney MJ (1995). Sex-specific effects of prenatal stress on hypothalamic-pituitaryadrenal responses to stress and brain glucocorticoid receptor density in adult rats. Brain Res Dev Brain Res 84: 55-61.
49. McGowan PO, Suderman M, Sasaki A, Huang TC, Hallett M, Meaney MJ et al (2011). Broad epigenetic signature of maternal care in the brain of adult rats. PLoS One 28: E14739.
50. Meaney MJ, Ferguson-Smith AC (2010). Epigenetic regulation of the neural transcriptome: The meaning of the marks. Nat Neurosci 13: 1313-1318.
51. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
52. Moore H (2010). The role of rodent models in the discovery of new treatments for schizophrenia: Updating our strategy. Schizophr Bull 36: 1066-1072.
53. Moreno JL, Kurita M, Holloway T, López J, Cadagan R, Martínez-Sobrido L et al (2011). Maternal influenza viral infection causes schizophrenia-like 5-HT2A and mGlu2 receptors in the adult offspring. J Neurosci 31: 1863-1872.
54. Morley-Fletcher S, Mairesse J, Soumier A, Banasr M, Fagioli F, Gabriel C et al (2011). Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 217: 301-313.
55. Nan X, Meehan RR, Bird A (1993). Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21: 4886-4892.
56. Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF et al (2007). Evidence for statistical epistasis between catechol-O- methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: Influence on risk of schizophrenia. Hum Genet 120: 889-906.
57. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD et al (2011). Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology 60: 1017-1041.
58. Niswender CM, Conn PJ (2010). Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322.
59. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 13: 1103-1108.
60. Pillai A (2008). Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals 16: 183-193.
61. Pin JP, Duvoisin R (1995). The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 34: 1-26.
62. Powell CM, Miyakawa T (2006). Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder? Biol Psychiatry 59: 1198-1207.
63. Roth TL, Lubin FD, Sodhi M, Kleinman JE (2009). Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 1790: 869-877.
64. Rybakowski JK (2008). BDNF gene: Functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9: 1589-1593.
65. Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A (2007). Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-Assisted microdissection. Mol Psychiatry 12: 385-397.
66. Schoepp DD, Marek GJ (2002). Molecular pharmacology of mGlu2/ 3 receptor agonists: Novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1: 215-225.
67. Shoval G, Weizman A (2005). The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
68. Spauwen J, Krabbendam L, Lieb R, Wittchen HU, Van Os J (2004). Early maternal stress and health behaviours and offspring expression of psychosis in adolescence. Acta Psychiatr Scand 110: 356-364.
69. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4: 131-144.
70. Szyf M (2011). DNA methylation, the early-life social environment and behavioral disorders. J Neurodev Disord 3: 238-249.
71. Toki S, Morinobu S, Imanaka A, Yamamoto S, Yamawaki S, Honma K (2007). Importance of early lighting conditions in maternal care by dam as well as anxiety and memory later in life of offspring. Eur J Neurosci 25: 815-829.
72. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G et al (2005). Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 57: 500-509.
73. Vallée M, Maccari S, Dellu F, Simon H, Le Moal M, Mayo W (1999). Long-term effects of prenatal stress and postnatal handling on age-related glucocorticoid secretion and cognitive performance: A longitudinal study in the rat. Eur J Neurosci 11: 2906-2916.
74. Van den Buuse M (2010). Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects. Schizophr Bull 36: 246-270.
75. Van Os J, Kenis G, Rutten BP (2010). The environment and schizophrenia. Nature 468: 203-212.
76. Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM et al (2007). Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res 91: 51-61.
77. Weaver IC, Meaney MJ, Szyf M (2006). Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 103: 3480-3485.
78. Zuena AR, Mairesse J, Casolini P, Cinque C, Alemá GS, Morley-Fletcher S et al (2008). Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One 3: E2170.